Purification method of vancomycin hydrochloride

Through the equilibrium and multi-step elution technology of UniPS series filler columns, the principle of competitive adsorption is used to solve the problem of low purity and yield in the purification of large-batch vancomycin hydrochloride, and the efficient vancomycin hydrochloride purification is achieved, which is suitable for industrialization Production.

CN115124601BActive Publication Date: 2024-11-12ZHE JIANG MEDICINE CO LTD XINCHANG PHARMA FAB
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202210912379.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-29
Publication Date
2024-11-12
Estimated Expiration
2042-07-29

AI Technical Summary

Technical Problem

The prior art cannot effectively handle the purification of large batches of vancomycin hydrochloride, resulting in low purity and yield of targets, especially on industrial scale, which is difficult to achieve efficient purification.

Method used

After equilibration using UniPS series filler columns, the upper column, the first elution and the second elution steps were used to compete for adsorption using a mixed solution of inorganic salt and ethanol, and the high-purity effluent was collected to obtain purified Wangu Hydrochloric acid. Aqueous solution of mycin.

Benefits of technology

It has achieved high purity (≥98%) and high yield (≥80%) in large batches of vancomycin hydrochloride, which reduces unit processing costs, improves production efficiency, and is suitable for industrial applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115124601B_ABST
    Figure CN115124601B_ABST
Patent Text Reader

Abstract

The present invention provides a method for purifying vancomycin hydrochloride, which comprises the following steps: balancing a packing column; adding an aqueous solution of vancomycin hydrochloride to be purified into the packing column to start loading, and collecting a first effective liquid; using a first eluent to perform a first elution on the packing column, and collecting a second effective liquid; using a second eluent to perform a second elution on the packing column, and collecting a third effective liquid; and obtaining a purified aqueous solution of vancomycin hydrochloride. The total amount of vancomycin hydrochloride in the aqueous solution of vancomycin hydrochloride to be purified accounts for 15 to 42% of the volume of the packing in the packing column. The present invention achieves the beneficial effect of obtaining the target vancomycin hydrochloride with high yield and purity by using the principle of competitive adsorption of the target substance and impurities in the liquid to be treated through the above-mentioned synergistic steps.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biopharmaceutical extraction and purification, and in particular to a method for purifying vancomycin hydrochloride. Background Art

[0002] Vancomycin hydrochloride is a glycopeptide antibiotic that can effectively treat some diseases caused by Staphylococcus aureus. At present, the purity of vancomycin hydrochloride produced in China is basically around 95%. In order to further improve the purity and other qualities of the product, narrow the gap with the original research product, or even achieve the goal of being better than the original research product, thereby enhancing the market competitiveness of the drug, we will consider further optimizing the process or adding subsequent purification steps.

[0003] The most commonly used purification technology for vancomycin hydrochloride is chromatographic separation and purification technology, but the prior art is mostly for small batch material purification, so it is impossible to effectively realize the purification process of large batch materials, and thus it is impossible to be effectively utilized in industry. The prior art generally adopts conventional chromatographic separation technology, and its column amount is inversely proportional to purity and yield. Specifically, after it selects an existing conventional filler, the column amount (processing capacity) is only 40% of the adsorption saturation amount, such as the adsorption saturation amount is 10% of the filler volume, then the column is only 4% of the column volume, wherein the column process is only an adsorption process (most of the impurities and all the target objects are adsorbed), there is no competitive adsorption process, and the column is eluted with an eluent after the end of the column, generally a part of the impurities are eluted with a low concentration of eluent, and then the target object is concentratedly washed with a high concentration of eluent, and the desorption of the target object and the filler is mainly driven by the eluent. If this separation and purification mode is adopted, after increasing the amount loaded on the column, the separation degree between the target and impurities will be affected, especially the cross-influence between impurities with similar physical and chemical properties to the target and the main components, which ultimately leads to low purity or yield of the target when processed in large quantities. Therefore, it is necessary to provide a new method for purifying vancomycin hydrochloride, which can effectively purify and process large quantities of liquid to be treated. Summary of the invention

[0004] The main purpose of the present invention is to provide a method for purifying vancomycin hydrochloride to solve the problem that the prior art cannot effectively process large quantities of materials when purifying crude vancomycin hydrochloride. In order to achieve the above purpose, according to one aspect of the present invention, a method for purifying vancomycin hydrochloride is provided, and the purification method comprises the following steps:

[0005] Step S1, balancing the packing column;

[0006] Step S2, adding the vancomycin hydrochloride aqueous solution to be purified into the packing column to start column loading, and collecting the effluent with a chromatographic purity of ≥97% during the column loading process as the first effective liquid;

[0007] Step S3, performing a first elution on the packing column using a first eluent, and collecting the effluent with a chromatographic purity of ≥97% during the first elution as a second effective liquid;

[0008] Step S4, performing a second elution on the packing column using a second eluent, and collecting the effluent with a chromatographic purity of ≥97% during the second elution as a third effective liquid;

[0009] Step S5, mixing the first effective liquid, the second effective liquid and the third effective liquid to obtain a purified vancomycin hydrochloride aqueous solution;

[0010] The filler in the packing column is one or more of UniPS 10-300, UniPS 20-300, UniPS 30-300 or UniPS40-300; the total amount of vancomycin hydrochloride in the vancomycin hydrochloride aqueous solution to be purified accounts for 15-42% of the volume of the filler in the packing column; the first eluent is an inorganic salt aqueous solution; and the second eluent is a mixed aqueous solution of an inorganic salt and ethanol.

[0011] Furthermore, the mass concentration of the vancomycin hydrochloride aqueous solution to be purified is 20000-50000 μg / mL; preferably, the pH value of the vancomycin hydrochloride aqueous solution to be purified is 3.0-3.5.

[0012] Furthermore, after step S1 and before step S2, the purification method further comprises: adding an inorganic salt with a mass concentration of 0.5-1.0% to the vancomycin hydrochloride aqueous solution to be purified, wherein the inorganic salt is ammonium chloride and / or sodium chloride.

[0013] Furthermore, the purity of the vancomycin hydrochloride aqueous solution to be purified is 93-95%; preferably, the filler in the filler column is UniPS 10-300.

[0014] Furthermore, in step S1, an inorganic salt aqueous solution with a mass concentration of 0.5-1.0% is used as a balancing agent to balance the filler column.

[0015] Furthermore, the volume dosage of the balancing agent is 0.5 to 2.0 times the volume of the filler in the packing column; preferably, the inorganic salt in the balancing agent is selected from ammonium chloride and / or sodium chloride.

[0016] Furthermore, in step S3, an inorganic salt aqueous solution with a mass concentration of 0.5-1.0% is used as the first eluent; preferably, the inorganic salt in the first eluent is selected from ammonium chloride and / or sodium chloride.

[0017] Furthermore, in step S4, in the second eluent, the mass concentration of the inorganic salt is 0.5-1.0%, and the mass concentration of ethanol is 10-15%; preferably, the inorganic salt in the second eluent is selected from ammonium chloride and / or sodium chloride.

[0018] Furthermore, after step S5, the purification method further comprises a step of regenerating the filler column.

[0019] Furthermore, in the regeneration agent, the mass concentration of ethanol is 30-70%, and the mass concentration of sodium hydroxide is 4-8%.

[0020] The present invention adopts the above-mentioned synergistic steps and utilizes the principle of competitive adsorption between the target substance and impurities in the liquid to be treated, thereby achieving the beneficial effect of obtaining the target substance vancomycin hydrochloride with high yield and purity by treating a large amount of liquid. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The drawings constituting a part of the present application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0022] Figure 1 shows a chromatogram of the vancomycin hydrochloride aqueous solution to be purified in Example 4 of the present invention; and

[0023] Figure 2 The chromatogram of the vancomycin hydrochloride aqueous solution after purification in Example 4 of the present invention is shown. DETAILED DESCRIPTION

[0024] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below with reference to the accompanying drawings and in combination with the embodiments.

[0025] Glossary:

[0026] Total: It refers to the mass of vancomycin hydrochloride in the solution, the unit is kg, which is equal to the concentration of vancomycin hydrochloride in the solution (kg / L) × volume (L).

[0027] As described in the background technology section of the present invention, the prior art has the problem of being unable to effectively process large quantities of materials when purifying crude vancomycin hydrochloride. In order to solve this problem, the present invention provides a method for purifying vancomycin hydrochloride, which comprises the following steps:

[0028] Step S1, balancing the packing column;

[0029] Step S2, adding the vancomycin hydrochloride aqueous solution to be purified into the packing column to start column loading, and collecting the effluent with a chromatographic purity of ≥97% during the column loading process as the first effective liquid;

[0030] Step S3, performing a first elution on the packing column using a first eluent, and collecting the effluent with a chromatographic purity of ≥97% during the first elution as a second effective liquid;

[0031] Step S4, performing a second elution on the packing column using a second eluent, and collecting the effluent with a chromatographic purity of ≥97% during the second elution as a third effective liquid;

[0032] Step S5, mixing the first effective liquid, the second effective liquid and the third effective liquid to obtain a purified vancomycin hydrochloride aqueous solution;

[0033] The filler in the packing column is one or more of UniPS 10-300, UniPS 20-300, UniPS 30-300 or UniPS40-300; the total amount of vancomycin hydrochloride in the vancomycin hydrochloride aqueous solution to be purified accounts for 15-42% of the volume of the filler in the packing column; the first eluent is an inorganic salt aqueous solution; and the second eluent is a mixed aqueous solution of an inorganic salt and ethanol.

[0034] The present invention adopts the above-mentioned coordinated steps of equilibrium-column loading-first elution-second elution, and utilizes the principle of competitive adsorption of the target and impurities in the liquid to be treated, so as to achieve the beneficial effect that a large amount of liquid can still be processed to obtain the target vancomycin hydrochloride with high yield and purity. Specifically, in step S1, the vancomycin hydrochloride aqueous solution to be purified is added to the packing column to start loading. In this process, impurities with weak adsorption (such as norvancomycin) flow out before the target vancomycin hydrochloride, impurities with strong adsorption (such as nitrogen methyl vancomycin) and a part of the target vancomycin hydrochloride are adsorbed on the packing column to the maximum adsorption saturation of the column, and another part of the target vancomycin hydrochloride flows through the column and continues to flow out. The first effective liquid of the present invention is this part of the flow-through liquid. In steps S2 and S3, the first elution and the second elution are continued for this part of the target vancomycin hydrochloride adsorbed on the column to collect the second effective liquid and the third effective liquid, so as to obtain the target vancomycin hydrochloride with high yield and purity. Furthermore, during the first elution and the second elution, the impurities with strong adsorptivity are always adsorbed on the packing column and do not flow out with the solution.

[0035] Based on this, the present invention effectively realizes the purification of a large amount of vancomycin hydrochloride aqueous solution to be purified, and the purity of the product can even reach more than 98%, and the yield can reach more than 80%. The above scheme of the present invention has a large raw material processing capacity, which can control the unit processing cost to a greater extent, thereby improving the production efficiency of actual production, and has a better prospect for industrial application.

[0036] It is additionally supplemented that, in addition to the target vancomycin hydrochloride, the above vancomycin hydrochloride aqueous solution to be purified also includes 1.0-1.5% of monodeschloromethyl vancomycin, 0.5-0.8% of norvancomycin, 0.4-0.7% of desamino vancomycin isomer 1, 0.3-0.6% of desamino vancomycin isomer 2, 0.6-0.9% of desasparagine-glutamine-vancomycin, 0.3-0.6% of nitrogen methyl vancomycin, and 0.2-0.5% of monosaccharide vancomycin, etc. It is also necessary to supplement that the present invention controls the total volume of vancomycin hydrochloride in the vancomycin hydrochloride aqueous solution to be purified to 15-42% of the volume of the packing in the packing column, so as to adsorb all impurities with strong adsorption on the packing column as much as possible, so as to avoid the impurities with strong adsorption from penetrating the column into the first effective liquid.

[0037] In a preferred embodiment, the mass concentration of the vancomycin hydrochloride aqueous solution to be purified used in the present invention is 20000-50000 μg / mL, the pH value is 3.0-3.5, and the purity is 93-95%. The test solution is more compatible with the above-mentioned preparation method of the present invention. Preferably, after step S1 and before step S2, the purification method also includes: adding an inorganic salt with a mass concentration of 0.5-1.0% to the vancomycin hydrochloride aqueous solution to be purified. Low concentrations of inorganic salts will promote the adsorption between the target and the filler. Adding an inorganic salt with a mass concentration of 0.5-1.0% to the upper column liquid can further increase the adsorption performance of the filler for vancomycin hydrochloride, thereby further increasing the processing capacity of each batch of upper columns.

[0038] In order to further improve the stability and purification effect of the purification process, it is preferred that in step S1, an inorganic salt aqueous solution with a mass concentration of 0.5-1.0% is used as a balancing agent to balance the packing column. More preferably, the volume of the balancing agent is 0.5-2.0 times the volume of the packing in the packing column, and the inorganic salt in the balancing agent is selected from ammonium chloride and / or sodium chloride.

[0039] In order to further improve the recovery rate and purity of the product, preferably in step S3, an inorganic salt aqueous solution with a mass concentration of 0.5-1.0% is used as the first eluent. The inorganic salt in the first eluent is selected from ammonium chloride and / or sodium chloride.

[0040] In order to further improve the recovery rate and purity of the product, preferably in step S4, the mass concentration of the inorganic salt in the second eluent is 0.5-1.0%, and the mass concentration of ethanol is 10-15%. The inorganic salt in the second eluent is selected from ammonium chloride and / or sodium chloride.

[0041] In a preferred embodiment, after step S5, the purification method further comprises the step of regenerating the filler column. Based on this, the impurities with strong adsorption properties adsorbed on the filler column can be eluted, and the filler column of the present invention can be recycled, so that the cost is lower in actual production. Preferably, the regeneration agent in the regeneration process is a mixed aqueous solution of ethanol and sodium hydroxide; more preferably, in the regeneration agent, the mass concentration of ethanol is 30-70%, and the mass concentration of sodium hydroxide is 4-8%.

[0042] The present application is further described in detail below in conjunction with specific embodiments. These embodiments should not be construed as limiting the scope of protection claimed in the present application.

[0043] Example 1

[0044] The polymer chromatographic filler of model UniPS 10-300 was loaded into the preparation column to form a filler column, and the column volume was controlled at 1000 mL. Then 10 g of ammonium chloride was dissolved in 2000 mL of purified water to form an inorganic salt aqueous solution with a mass concentration of 0.5% and pumped into the filler column as a balance agent for balance.

[0045] Take 7.2L of vancomycin hydrochloride aqueous solution with a mass concentration of 21263μg / mL and a purity of 93.82% as the column liquid, add 72g of ammonium chloride to it, and adjust its pH value to 3.00 with hydrochloric acid, then pump the column liquid into the column for column loading, and collect the effluent with a chromatographic purity of more than 97% as the first effective liquid. (Comment reply: Adding sodium chloride or ammonium chloride to the column liquid is mainly to increase the adsorption performance of the filler, thereby increasing the processing capacity of each batch of column loading. The main principle is that low concentrations of inorganic salts will promote the adsorption between the product and the filler)

[0046] 40 g of ammonium chloride was dissolved in 4000 mL of purified water to form an inorganic salt aqueous solution with a mass concentration of 1%, which was used as the first eluent and pumped into the above-mentioned packing column for the first elution. The effluent with a chromatographic purity of ≥97% during the first elution was collected as the second effective liquid.

[0047] Dissolve 20 g of ammonium chloride in 4000 mL of an aqueous solution containing 10% ethanol to form a second eluent with an inorganic salt mass concentration of 0.5% and an ethanol concentration of 10% for a second elution, and collect the effluent with a chromatographic purity of ≥97% during the second elution as the third effective liquid.

[0048] 160 g of sodium hydroxide was dissolved in 2000 mL of an aqueous solution containing 30% ethanol to form a regeneration agent with a sodium hydroxide mass concentration of 8% and an ethanol concentration of 30%, and then pumped into the column for regeneration. After the regeneration, the column was washed with purified water until the ethanol concentration of the effluent was 0, so that the column could be used for the next round of operation.

[0049] The first effective liquid, the second effective liquid and the third effective liquid are combined and collected to obtain the target purified liquid.

[0050] Example 2

[0051] The only difference from Example 1 is:

[0052] 10 g of ammonium chloride was dissolved in 1000 mL of purified water to form an inorganic salt aqueous solution with a mass concentration of 1% as a balancing agent.

[0053] 9.5 L of vancomycin hydrochloride aqueous solution with a concentration of 42236 μg / mL and a purity of 93.58% was taken as the upper column liquid, and 142.5 g of ammonium chloride was added, and the pH value was adjusted to 3.21 with hydrochloric acid.

[0054] 20 g of ammonium chloride was dissolved in 4000 mL of purified water to form an inorganic salt aqueous solution with a mass concentration of 1% as the first eluent.

[0055] 40 g of ammonium chloride was dissolved in 4000 mL of an aqueous solution containing 12% ethanol to form a second eluent having an inorganic salt mass concentration of 1% and an ethanol concentration of 12%.

[0056] The mass concentration of ethanol in the regeneration agent is 45%.

[0057] Example 3

[0058] The only difference from Example 1 is:

[0059] 4.7 L of vancomycin hydrochloride aqueous solution with a concentration of 83548 μg / mL and a purity of 93.60% was taken as the upper column liquid, 47 g of sodium chloride was added, and the pH was adjusted to 3.35 with hydrochloric acid.

[0060] 40 g of sodium chloride was dissolved in 4000 mL of an aqueous solution containing 13% ethanol to form a second eluent having an inorganic salt mass concentration of 1% and an ethanol concentration of 13%.

[0061] 120 g of sodium hydroxide was dissolved in 2000 mL of an aqueous solution containing 55% ethanol to form a regeneration agent having a sodium hydroxide mass concentration of 6% and an ethanol concentration of 55%.

[0062] Example 4

[0063] The only difference from Example 1 is:

[0064] 10 g of sodium chloride was dissolved in 1000 mL of purified water to form an inorganic salt aqueous solution with a mass concentration of 1% as a balancing agent.

[0065] 4 L of vancomycin hydrochloride aqueous solution with a concentration of 99915 μg / mL and a purity of 93.62% was taken as the upper column liquid, and 60 g of sodium chloride was added, and the pH was adjusted to 3.50 with hydrochloric acid.

[0066] Dissolve 20 g of sodium chloride in 4000 mL of purified water as the first eluent.

[0067] 40 g of sodium chloride was dissolved in 4000 mL of an aqueous solution containing 15% ethanol as the second eluent.

[0068] 80 g of sodium hydroxide was dissolved in 2000 mL of an aqueous solution containing 70% ethanol as a regeneration agent.

[0069] Figure 1 The chromatogram of the vancomycin hydrochloride aqueous solution to be purified in Example 4 is shown.

[0070] Figure 2 The chromatogram of the vancomycin hydrochloride aqueous solution after purification in Example 4 is shown.

[0071] Comparative Example 1

[0072] The only difference from Example 4 is that:

[0073] The amount of vancomycin hydrochloride aqueous solution used is 4.3L.

[0074] Performance characterization:

[0075] The performance tests were carried out on the products in the embodiments and comparative examples, and the test results are shown in Table 1 below.

[0076] Table 1

[0077] purity Yield Absorbance Example 1 98.18% 78.9% 0.016 Example 2 98.10% 80.9% 0.011 Example 3 98.00% 80.2% 0.015 Example 4 98.13% 80.0% 0.013 Comparative Example 1 97.21% 71.3% 0.020

[0078] By comparing Example 4 with Comparative Example 1, it can be found that when the amount loaded on the column exceeds 42%, it is not conducive to the competitive adsorption separation of impurities and main components, the purification effect is poor, and the yield is reduced while ensuring the purity of the effective liquid.

[0079] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for purifying vancomycin hydrochloride, characterized in that: The purification method comprises the following steps: Step S1, balancing the packing column; Step S2, adding the vancomycin hydrochloride aqueous solution to be purified into the packing column to start column loading, and collecting the effluent with a chromatographic purity of ≥97% during the column loading process as the first effective liquid; Step S3, performing a first elution on the packing column using a first eluent, and collecting the effluent with a chromatographic purity of ≥97% during the first elution as a second effective liquid; Step S4, performing a second elution on the packing column using a second eluent, and collecting the effluent with a chromatographic purity of ≥97% during the second elution as a third effective liquid; Step S5, mixing the first effective liquid, the second effective liquid and the third effective liquid to obtain a purified vancomycin hydrochloride aqueous solution; wherein: The filler in the packing column is one or more of UniPS10-300, UniPS20-300, UniPS 30-300 or UniPS 40-300; The total amount of vancomycin hydrochloride in the vancomycin hydrochloride aqueous solution to be purified accounts for 15 to 42% of the volume of the filler in the filler column; the pH value of the vancomycin hydrochloride aqueous solution to be purified is 3.0 to 3.5; The first eluent is an inorganic salt aqueous solution; the second eluent is a mixed aqueous solution of an inorganic salt and ethanol; the first eluent is an inorganic salt aqueous solution with a mass concentration of 0.5-1.0%; in the second eluent, the mass concentration of the inorganic salt is 0.5-1.0% and the mass concentration of ethanol is 10-15%.

2. The method for purifying vancomycin hydrochloride according to claim 1, characterized in that: The mass concentration of the vancomycin hydrochloride aqueous solution to be purified is 20000-50000 μg / mL.

3. The method for purifying vancomycin hydrochloride according to claim 2, characterized in that: The purity of the vancomycin hydrochloride aqueous solution to be purified is 93-95%.

4. The method for purifying vancomycin hydrochloride according to any one of claims 1 to 3, characterized in that: After step S1 and before step S2, the purification method further comprises: adding an inorganic salt with a mass concentration of 0.5-1.0% to the vancomycin hydrochloride aqueous solution to be purified, wherein the inorganic salt is ammonium chloride and / or sodium chloride.

5. The method for purifying vancomycin hydrochloride according to any one of claims 1 to 3, characterized in that: In the step S1, an inorganic salt aqueous solution with a mass concentration of 0.5-1.0% is used as a balancing agent to balance the filler column.

6. The method for purifying vancomycin hydrochloride according to claim 5, characterized in that: The volume dosage of the balancing agent is 0.5 to 2.0 times the volume of the filler in the filler column.

7. The method for purifying vancomycin hydrochloride according to claim 6, characterized in that: The inorganic salt in the balancing agent is selected from ammonium chloride and / or sodium chloride.

8. The method for purifying vancomycin hydrochloride according to any one of claims 1 to 3, characterized in that: The inorganic salt in the first eluent is selected from ammonium chloride and / or sodium chloride.

9. The method for purifying vancomycin hydrochloride according to any one of claims 1 to 3, characterized in that: The inorganic salt in the second eluent is selected from ammonium chloride and / or sodium chloride.

10. The method for purifying vancomycin hydrochloride according to any one of claims 1 to 3, characterized in that: After step S5, the purification method further comprises a step of regenerating the filler column.

11. The method for purifying vancomycin hydrochloride according to claim 10, characterized in that: The regeneration agent in the regeneration process is a mixed aqueous solution of ethanol and sodium hydroxide.

12. The method for purifying vancomycin hydrochloride according to claim 11, characterized in that: In the regeneration agent, the mass concentration of ethanol is 30-70%, and the mass concentration of sodium hydroxide is 4-8%.

Citation Information

Patent Citations

  • Method for purifying glycopeptide compound

    CN102050866A

  • Extraction and purification technology of four kinds of flavone C-glycosides in moso bamboo leaves

    CN104557893A

  • Separation and purification method of high-purity vancomycin hydrochloride

    CN104610434A